JP2015517563A - Ｋｖ３阻害剤としてのヒダントイン誘導体 - Google Patents

Ｋｖ３阻害剤としてのヒダントイン誘導体 Download PDF

Info

Publication number
JP2015517563A
JP2015517563A JP2015513268A JP2015513268A JP2015517563A JP 2015517563 A JP2015517563 A JP 2015517563A JP 2015513268 A JP2015513268 A JP 2015513268A JP 2015513268 A JP2015513268 A JP 2015513268A JP 2015517563 A JP2015517563 A JP 2015517563A
Authority
JP
Japan
Prior art keywords
compound
alkyl
halo
oxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015513268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517563A5 (enExample
Inventor
ラージ チャールズ
ラージ チャールズ
Original Assignee
アウトイフオンイ トヘラペウトイクス リミテッド
アウトイフオンイ トヘラペウトイクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1209013.0A external-priority patent/GB201209013D0/en
Priority claimed from GBGB1209986.7A external-priority patent/GB201209986D0/en
Priority claimed from GBGB1222528.0A external-priority patent/GB201222528D0/en
Application filed by アウトイフオンイ トヘラペウトイクス リミテッド, アウトイフオンイ トヘラペウトイクス リミテッド filed Critical アウトイフオンイ トヘラペウトイクス リミテッド
Publication of JP2015517563A publication Critical patent/JP2015517563A/ja
Publication of JP2015517563A5 publication Critical patent/JP2015517563A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015513268A 2012-05-22 2013-05-22 Ｋｖ３阻害剤としてのヒダントイン誘導体 Pending JP2015517563A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1209013.0 2012-05-22
GBGB1209013.0A GB201209013D0 (en) 2012-05-22 2012-05-22 Novel compounds
GBGB1209986.7A GB201209986D0 (en) 2012-06-06 2012-06-06 Novel compounds
GB1209986.7 2012-06-06
GBGB1222528.0A GB201222528D0 (en) 2012-12-13 2012-12-13 Novel uses
GB1222528.0 2012-12-13
PCT/GB2013/051343 WO2013175211A1 (en) 2012-05-22 2013-05-22 Hydantoin derivatives as kv3 inhibitors

Publications (2)

Publication Number Publication Date
JP2015517563A true JP2015517563A (ja) 2015-06-22
JP2015517563A5 JP2015517563A5 (enExample) 2016-07-07

Family

ID=48534442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513268A Pending JP2015517563A (ja) 2012-05-22 2013-05-22 Ｋｖ３阻害剤としてのヒダントイン誘導体

Country Status (7)

Country Link
US (1) US9669030B2 (enExample)
EP (1) EP2852588B8 (enExample)
JP (1) JP2015517563A (enExample)
CN (1) CN104334548A (enExample)
BR (1) BR112014028718A2 (enExample)
IN (1) IN2014KN02409A (enExample)
WO (1) WO2013175211A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502696A (ja) * 2015-12-16 2019-01-31 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３チャネルのヒダントインモジュレーター
JP2022502370A (ja) * 2018-09-21 2022-01-11 バイオノミクス リミテッド 置換ピリジニル化合物およびその使用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012015868A2 (pt) 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
FI3867247T3 (fi) * 2018-10-16 2024-10-30 Autifony Therapeutics Ltd Uusia yhdisteitä
US12358901B2 (en) * 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
AU2019296526A1 (en) * 2019-03-25 2021-09-16 Bionomics Limited Substituted-N-heteroaryl compounds and uses thereof
BR112022013339A2 (pt) 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
WO2023017263A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives
JP2014516073A (ja) * 2011-06-07 2014-07-07 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US6002016A (en) 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
WO1996036633A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
CZ394097A3 (cs) 1995-06-20 1998-09-16 E. I. Du Pont De Nemours And Company Artropodicidní a fungicidní amidy
WO1998005652A2 (en) 1996-08-01 1998-02-12 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
WO1998023156A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Methyl substituted fungicides and arthropodicides
AU6040398A (en) 1997-01-30 1998-08-25 E.I. Du Pont De Nemours And Company Fungicidal compositions
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
RU2230551C2 (ru) 1999-07-23 2004-06-20 ШИОНОГИ энд КО, ЛТД. Ингибиторы th2-дифференцировки
EP1273287A1 (en) 2000-04-04 2003-01-08 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
WO2003048134A1 (en) 2001-12-05 2003-06-12 Japan Tobacco Inc. Triazole compound and medicinal use thereof
CA2475767A1 (en) 2002-02-07 2003-08-14 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
HUP0401523A3 (en) * 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
RS52274B2 (sr) 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PL3412290T3 (pl) 2006-03-27 2021-09-06 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
EP2481736A1 (en) 2007-04-20 2012-08-01 Deciphera Pharmaceuticals, LLC. Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2009097997A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
SG172778A1 (en) 2008-12-22 2011-08-29 Hoffmann La Roche Heterocyclic antiviral compounds
WO2011073114A1 (en) 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2012076877A1 (en) * 2010-12-06 2012-06-14 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
FR2968721B1 (fr) * 2010-12-09 2015-07-24 Valeo Equip Electr Moteur Circuit de demarreur pour vehicule automobile comportant un dispositif de rehaussement de tension de batterie et demarreur equipe
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
CA2856654C (en) 2011-12-06 2020-03-31 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
CN104334547B (zh) * 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives
JP2013513564A (ja) * 2009-12-11 2013-04-22 アウトイフオンイ トヘラペウトイクス リミテッド イミダゾリジンジオン誘導体
JP2014516073A (ja) * 2011-06-07 2014-07-07 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502696A (ja) * 2015-12-16 2019-01-31 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３チャネルのヒダントインモジュレーター
JP7036725B2 (ja) 2015-12-16 2022-03-15 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３チャネルのヒダントインモジュレーター
JP2022502370A (ja) * 2018-09-21 2022-01-11 バイオノミクス リミテッド 置換ピリジニル化合物およびその使用

Also Published As

Publication number Publication date
EP2852588B1 (en) 2017-11-29
WO2013175211A1 (en) 2013-11-28
IN2014KN02409A (enExample) 2015-05-01
CN104334548A (zh) 2015-02-04
BR112014028718A2 (pt) 2017-06-27
US9669030B2 (en) 2017-06-06
EP2852588B8 (en) 2018-01-10
US20150157631A1 (en) 2015-06-11
EP2852588A1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
US9669030B2 (en) Hydantoin derivatives as Kv3 inhibitors
US11180461B2 (en) Triazoles as Kv3 inhibitors
US11583527B2 (en) Hydantoin derivatives useful as Kv3 inhibitors
WO2013182851A1 (en) Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
CN103596943B (zh) 用作kv3抑制剂的乙内酰脲衍生物
JP2025003958A (ja) 疼痛を治療するためのｋｖ３チャネルのモジュレーター
EP3390394B1 (en) Hydantoin modulators of kv3 channels
BR112014013400B1 (pt) Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181204